Recombinant human alpha-Synuclein (lyophilized) protein , 1-140aa

Recombinant human alpha-Synuclein (lyophilized) protein , 1-140aa

Catalog Number:
P001444562NKM
Mfr. No.:
SNA2001L
Price:
$210
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

      • Properties
        • Protein Name
          SNCA, NACP, PARK1, alpha-Synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Alpha synuclein, Alpha-synuclein isoform NACP140, alphaSYN, MGC105443, MGC110988, MGC127560, MGC64356, Non A beta component of AD amyloid, Non A4 component of amyloid precursor, Non-A-beta component of alzheimers disease amyloid, precursor of PARK 1, PARK 4, PARK4, Parkinson disease familial 1, PD 1, PD1, Synuclein alpha
          Type
          Recombinant Proteins
          Purification
          > 95% by SDS-PAGE
          Formulation
          Lyophilized from a 0.2 um filtered in 20mM Tris-HCl buffer (pH 7.5) containing 100mM NaCl, 1mM MgCl2
          Storage
          Stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.
          Concentration
          Reconstitute in sterile distilled water at a concentration of 1mg/ml or less.
          Molecular Weight
          14.4 kDa (140aa) confirmed by MALDI-TOF (Molecular weight on SDS-PAGE will appear higher)
          Expression system
          E.coli

          More Information

          UniProt
          P37840

          * For research use only. Not intended for human, diagnostics or veterinary use.

      • Applications
        • Application
          SDS-PAGE
      • Reference
        • Lu J, et al. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinsons disease. (J Neuroinflammation. 2022)
          Wang D, et al. Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming. (Acta Pharm Sin B. 2023)
          Lee J, et al. Targeted degradation of ⍺-synuclein aggregates in Parkinsons disease using the AUTOTAC technology. (Mol Neurodegener. 2023)

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.